Company Insights

AVNS customer relationships

Explore interactive graphBrowse insights index
AVNS customer relationship map

Avanos Medical (AVNS) — Customer Relationships and Commercial Risk Profile

Avanos Medical manufactures and markets medical devices—notably enteral feeding systems and related disposables—and monetizes through product sales to hospitals, health systems and wholesale distributors, with a meaningful portion contracted through Group Purchasing Organizations (GPOs) and multi‑year supply agreements. Revenue is concentrated in a handful of product lines (MIC‑KEY, Corpak and NeoMed) and routed predominantly through distributors; corporate strategy since 2023 has included targeted divestitures to sharpen margins and focus on higher‑margin chronic care and pain management devices. For investors evaluating counterparty exposure and commercial durability, the documented counterparties and contract characteristics point to a distributor‑centric, repeat‑order business with both structural strengths and concentration risks.
Explore detailed counterparty intelligence at https://nullexposure.com/.

Executive takeaways for investors

Avanos is a manufacturing and distribution business with predictable ordering mechanics and concentrated product economics. Key points:

  • Distribution‑led go‑to‑market: Roughly half of North American sales flow through third‑party distributors and about 54% of consolidated net sales are to distributors globally.
  • Contracting posture: The company operates under supply agreements and GPO arrangements that are typically multi‑year (three‑year renewal cadence), creating predictable if not exclusive demand streams.
  • Product concentration: Several product lines each contribute more than 10% of consolidated net sales, creating single‑product economic sensitivity.
  • Active portfolio reshaping: Management has divested lower‑fit businesses (Respiratory Health, HA product line, rental businesses) to reallocate capital and simplify the commercial footprint.

How Avanos actually contracts and collects

The company’s commercial mechanics are straightforward and investor‑friendly in transparency: supply agreements commonly run for three years, customers place purchase orders, and Avanos’s performance obligation is typically limited to shipment or delivery. GPO arrangements also underpin a substantial share of sales; these agreements are renewed on roughly a three‑year cadence and involve fee arrangements that are recorded as reductions of net sales. Collectively, these features produce a revenue profile that is recurrent and order‑driven rather than project‑oriented.

These contract attributes produce several company‑level signals investors should weigh:

  • Contract length and renewal cadence: Multi‑year terms provide demand visibility but do not necessarily lock in exclusivity.
  • Revenue concentration: The business is product‑concentrated, which amplifies operational and market risks if any core product line underperforms.
  • Distributor dependence: With a majority of sales routed through distributors and distributor rebates material to net sales, counterparty credit and distributor channel economics are critical to performance.
  • Simplicity of fulfillment: Obligations are generally shipment/delivery focused, reducing long‑tail service liabilities and complexity in revenue recognition.

For more structured counterparty workstreams and primary‑source tracking, see https://nullexposure.com/.

Documented counterparties and related events

Below are every relationship result surfaced in the available records, presented with concise summaries and source context.

  • Owens & Minor — MassDevice (FY2018): A news report noted Halyard (the predecessor business) closed a $710 million sale of its surgical and infection prevention business to Owens & Minor, an event that precipitated Halyard’s pivot to what became Avanos. This transaction is documented in coverage of FY2018 activity.
    Source: MassDevice reporting on the FY2018 sale to Owens & Minor.

  • Owens & Minor — Medical Design & Outsourcing (FY2018): Coverage reiterated that Owens & Minor acquired Halyard Health’s surgical and infection prevention product lines, which were central to the prior Halyard identity and informed the subsequent rebranding to Avanos. This reporting explains the antecedent corporate repositioning in 2018.
    Source: Medical Design & Outsourcing, FY2018 coverage of the Halyard/Owens & Minor transaction.

  • SunMed Group Holdings, LLC — PR Newswire (FY2023): Avanos publicly announced a definitive agreement to sell its Respiratory Health business to SunMed Group Holdings, LLC, documenting a completed strategic divestiture in 2023. The press release frames the move as a deliberate carve‑out.
    Source: PR Newswire release, Avanos announcement (FY2023).

  • SunMed Group Holdings, LLC — TradingView summary (FY2026 report referencing FY2025 actions): Subsequent filings and summaries note that Avanos sold its Respiratory Health business to SunMed in 2023 and completed additional divestitures (HA product line and Game Ready rental business) in 2025 as part of a transformation initiative to refocus the business.
    Source: TradingView coverage summarizing Avanos SEC disclosures and transformation activity (referencing FY2026 materials).

  • SunMed — Plastics News (FY2023): Industry reporting quantified the transaction with an acquisition price—SunMed’s purchase of Avanos’s respiratory unit was reported at approximately $110 million—providing a market price reference for the divestiture.
    Source: Plastics News reporting (FY2023).

Commercial and financial implications

The documented counterparties and corporate actions create a clear set of investment implications:

  • Positive: focused product portfolio and predictable order mechanics. Avanos’s go‑to‑market through distributors and GPOs delivers scale advantages and recurring orders, which supports stable gross margins in core products. The divestitures reduce non‑strategic complexity and can improve capital allocation.
  • Negative: concentration and channel dependency. With multiple product lines individually accounting for more than 10% of sales and distributors accounting for the majority of revenue, Avanos is exposed to product‑specific shocks and distributor contract renegotiation risk. Distributor rebates and GPO fees also compress reported net sales and require attentive margin modeling.
  • Counterparty event risk is observable. The sale of respiratory assets to SunMed and prior portfolio moves tied to the Owens & Minor transaction highlight that Avanos’s commercial footprint has shifted materially in recent years; investors should treat historical revenue mixes as transitional.

What investors should do next

  • Review recent 10‑Ks and the company’s FY2024–FY2025 filings for updated disclosures on distributor concentration, GPO economics and the financial impact of divestitures.
  • Monitor distributor credit metrics and GPO contract renewal timing to model downside scenarios for order flow.
  • Track any further strategic divestitures or bolt‑on acquisitions that change the product mix or reduce concentration.

For continuous counterparty and contract intelligence on Avanos and comparable med‑tech companies, visit https://nullexposure.com/.
For bespoke research or to commission a counterparty risk brief, start at https://nullexposure.com/.

Summary: Avanos is a distributor‑centric medical device company with concentrated product economics and multi‑year contracting posture; recent divestitures to SunMed and historical transactions tied to Owens & Minor have materially reshaped its commercial map and should be central to investor due diligence.